Charles Schwab
AVIR icon

Charles Schwab’s Atea Pharmaceuticals AVIR Stock Holding History

Charles Schwab’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.84M Buy
610,607
+13,898
+2% +$69.1K ﹤0.01% 2668
2026
Q1 		$3.21M Sell
596,709
-11,083
-2% -$50.9K ﹤0.01% 2579
2025
Q4 		$2.17M Sell
607,792
-17,192
-3% -$54.6K ﹤0.01% 2738
2025
Q3 		$1.81M Sell
624,984
-10,298
-2% -$35.2K ﹤0.01% 2776
2025
Q2 		$2.29M Buy
635,282
+27,400
+5% +$81.7K ﹤0.01% 2623
2025
Q1 		$1.82M Sell
607,882
-51,645
-8% -$161K ﹤0.01% 2646
2024
Q4 		$2.21M Buy
659,527
+9,370
+1% +$31.1K ﹤0.01% 2646
2024
Q3 		$2.18M Buy
650,157
+50,794
+8% +$184K ﹤0.01% 2685
2024
Q2 		$1.98M Sell
599,363
-12,956
-2% -$48.3K ﹤0.01% 2701
2024
Q1 		$2.47M Buy
612,319
+27,993
+5% +$110K ﹤0.01% 2535
2023
Q4 		$1.78M Buy
584,326
+2,093
+0.4% +$6.34K ﹤0.01% 2655
2023
Q3 		$1.75M Buy
582,233
+8,274
+1% +$28.2K ﹤0.01% 2640
2023
Q2 		$2.15M Buy
573,959
+47,610
+9% +$178K ﹤0.01% 2526
2023
Q1 		$1.76M Sell
526,349
-38,145
-7% -$155K ﹤0.01% 2558
2022
Q4 		$2.72M Buy
564,494
+11,170
+2% +$56.5K ﹤0.01% 2463
2022
Q3 		$3.15M Buy
553,324
+125,603
+29% +$961K ﹤0.01% 2441
2022
Q2 		$3.04M Buy
427,721
+13,124
+3% +$89.6K ﹤0.01% 2409
2022
Q1 		$2.99M Buy
414,597
+19,350
+5% +$131K ﹤0.01% 2509
2021
Q4 		$3.53M Buy
395,247
+2,068
+0.5% +$32.2K ﹤0.01% 2524
2021
Q3 		$13.8M Buy
393,179
+196,840
+100% +$5.46M ﹤0.01% 1825
2021
Q2 		$4.22M Buy
196,339
+107,499
+121% +$3.23M ﹤0.01% 2430
2021
Q1 		$5.49M Buy
88,840
+2,406
+3% +$163K ﹤0.01% 2253
2020
Q4 		$3.61M Buy
+86,434
New +$2.79M ﹤0.01% 2375

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Charles Schwab's AVIR Position: Q2 2026 in Review

Charles Schwab increased its Atea Pharmaceuticals (AVIR) stake by 2.3% in Q2 2026, buying an estimated $69.1K and bringing the position to 610,607 shares worth $2.84M. The position accounts for ﹤0.01% of the portfolio, ranked #2668.

Charles Schwab first reported a position in AVIR in Q4 2020 and has held it in 23 quarters since. The position peaked at $13.8M in Q3 2021. 125 funds tracked by Wall St. Rank hold AVIR as of Q2 2026.

  • Charles Schwab held 610,607 shares of Atea Pharmaceuticals worth $2.84M as of Q2 2026.
  • Charles Schwab bought 13,898 Atea Pharmaceuticals shares in Q2 2026, an estimated $69.1K.
  • Atea Pharmaceuticals made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #2668 holding.
  • Charles Schwab first reported a position in Atea Pharmaceuticals in Q4 2020 and has held it in 23 quarters since.
  • Charles Schwab's Atea Pharmaceuticals position peaked at $13.8M in Q3 2021.
  • 125 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.